Imatinib Completed Phase 2 Trials for Melanoma / Skin Neoplasms Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00027586Imatinib Mesylate in Treating Patients With Metastatic Melanoma